The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. It targets older adults (≥60 years) who engage in seasonal migration between cold (Heilongjiang) and tropical (Hainan) regions. The primary objective is to investigate cardiovascular and metabolic disease risks, underlying biological and environmental mechanisms, and effective preventive strategies in this unique population. Participants are recruited from both origin and destination sites and undergo standardized baseline assessments, including questionnaires, physical examinations, medical imaging, biospecimen collection (blood, stool, hair, nails), and environmental exposure monitoring. Longitudinal follow-up includes periodic reassessments, remote monitoring, and data linkage with hospital information systems to capture health outcomes. The study aims to: Define migration-related health risk profiles and disease phenotypes. Elucidate biological and environmental mechanisms influencing disease onset and progression. Develop AI-driven risk prediction models and evaluate targeted interventions through nested randomized controlled trials. Translate findings into clinical guidelines and scalable cross-regional health management models. This is the first cohort in China to systematically investigate the health impacts of seasonal migration in older adults. By integrating epidemiology, multi-omics, environmental data, and health policy translation, the study seeks to improve continuity of care, strengthen climate adaptation, and promote healthy ageing.
Study Type
OBSERVATIONAL
Enrollment
26,000
no intervention
Harbin Medical University
Harbin, Heilongjiang, China
RECRUITINGNumber of Participants Experiencing First Major Cardiovascular Event
First occurrence of myocardial infarction, stroke (ischemic or hemorrhagic), or cardiovascular death, confirmed through hospital records, death registries, and adjudication committee review.
Time frame: Up to 5 years from baseline
Number of Participants with New-Onset Metabolic Disorders
New-onset type 2 diabetes mellitus, dyslipidemia, or obesity as defined by standard clinical and laboratory criteria.
Time frame: Up to 5 years from baseline
Number of Deaths from Any Cause
Death from any cause, verified through official death certificates and hospital records.
Time frame: Up to 5 years from baseline
Changes in Cardiometabolic Risk Factors
Longitudinal changes in blood pressure, fasting glucose, HbA1c, lipid profile, BMI, waist circumference, and body composition.
Time frame: Baseline, 2 years, 4 years
Change in EQ-5D Quality of Life Score from Baseline
Changes in validated quality-of-life scales (e.g., EQ-5D).
Time frame: Baseline, 2 years, 4 years
Change in Cognitive Function Score (MoCA) from Baseline
Mean change in Montreal Cognitive Assessment score.
Time frame: Baseline, 2 years, 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.